Comparison of tetrahydrocannabinol and synhexyl in man
Leo E. Hollister, R. K. Richards, H. K. Gillespie
Clinical Pharmacology & Therapeutics November 1, 1968 DOI: 10.1002/cpt196896783 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Observational cohort Peer reviewed |
|---|---|
| Sample size | 16 |
| Population | Volunteer subjects |
| Interventions | THC synhexyl |
| Dose | THC: 341 to 946 µg/kg (median 581); synhexyl: 633 to 2,666 µg/kg (median 1,370) |
| Topics | Cannabis |
| Keywords | Euphoriant Volunteer Sedation Dronabinol Pharmacology Toxicology |
| Citations | 195 |
| Key findings | Synhexyl produced clinical effects similar to THC but was slower in onset and about one third as potent, with effects at higher doses resembling LSD but with more sedation, longer euphoria, and no sympathomimetic effects. |
Abstract
A synthetic isomer of tetrahydrocannabinol (1‐Δ'‐3,4‐transtetrahydrocannabinol), believed to be identical to the most active naturally occurring THC, was compared with a semisynthetic THC‐like compound, synhexyl. Sixteen volunteer subiects received THC in doses ranging from 341 to 946 p.g per kilo gram (median 581). Thirteen subjects received synhexyl in doses ranging from 633 to 2,666 µg per kilogram (median 1,370). Clinical syndromes tram the 2 drugs were similar, although synhexyl was slower in onset and only about one third as potent. The clinical effects resembled those of psychotomimetics such as LSD, at least at the higher doses. These drugs differed from LSD in the following respects: sedation was prominent; euphoria was langer lasting; dreamlike sequences more pronounced; and physiological and biochemical effects were somewhat different, especially in the absence of sympathomimetic effects.
Comparable studies
Other observational and cohort studies on cannabis, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| High-potency cannabis and the risk of psychosis People with first episode of psychosis and healthy controls from the local population | 2009 | Case-control study | n = 454 |
| Ayahuasca-Assisted Therapy for Addiction: Results from a Preliminary Observational Study in Canada Rural aboriginal population | 2013 | Observational study | |
| Impaired cognitive performance in drug free users of recreational ecstasy (MDMA) Otherwise healthy young people | 2000 | Observational | |
| Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study Individuals from the general population in Germany aged 14-24 at baseline | 2011 | Observational cohort | n = 1,923 |
| Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases Patients treated for cannabis-induced psychotic symptoms in Denmark between 1994 and... | 2005 | Observational cohort | n = 535 |
Citations in the library
Cited by 10
- Evaluation of cannabimimetic effects of selected minor cannabinoids and Terpenoids in mice. Progress in Neuro-Psychopharmacology and Biological Psychiatry June 8, 2024
- Hallucinogens as discriminative stimuli in animals: LSD, phenethylamines, and tryptamines. Psychopharmacology April 2009
- Biomarkers for the effects of cannabis and THC in healthy volunteers. British Journal of Clinical Pharmacology January 2009
- Effects of acute marijuana smoking on pulse rate and mood states in women. Psychopharmacology 1984
- Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology 1982
and 5 more in the library